Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 3, 2010, Pages 335-339

  Montero, M ^a   Sala, M ^b   Riu, M ^b   Belvis, F ^b   Salvado, M ^c   Grau, S ^b   Horcajada, J P ^a   Alvarez Lerma, F ^b   Terradas, R ^b   Orozco Levi, M ^b,d,e   Castells, X ^b   Knobel, H ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c Laboratori de Referencia de Catalunya   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; COLISTIN; MONOBACTAM DERIVATIVE; PENICILLIN G; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIDRUG RESISTANCE; PATIENT SELECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR; UNIVERSITY HOSPITAL; VENTILATOR ASSOCIATED PNEUMONIA; WARD;

AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 77952422047     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-009-0850-1     Document Type: Article

References (14)

1. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50:43-48
2. Falagas ME, Bliziotis IA (2007) Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29:630-636
3. Cao B, Wang H, Sun H, Zhu Y, Chen M (2004) Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 57:112-118
4. Cipriano Souza R, Vicente AC, Vieira VV, Marques SG, Soares MG, Moura MC, Koifman RJ (2008) Clindamycin and metronidazole as independent risk factors for nosocomial acquisition of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect 69 (4):402-403
5. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A (2004) Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 38:670-677
6. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC (2002) Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 34(3):340-345
7. El Amari EB, Chamot E, Auckenthaler R, Pechère JC, Van Delden C (2001) Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 33:1859-1864
8. D'Agata EMC (2005) Methodologic issues of case-control studies: a review of established and newly recognized limitations. Infect Control Hosp Epidemiol 26:338-341
9. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y (2002) Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 34 (12):1558-1563
10. Zavascki AP, Cruz RP, Goldani LZ (2005) Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 59(2):96-101
11. Lieberman D, Lieberman D (2003) Pseudomonal infections in patients with COPD: epidemiology and management. Am J Respir Med 2:459-468
12. Harris AD, McGregor JC, Furuno JP (2006) What infection control interventions should be undertaken to control multidrugresistant gram-negative bacteria? Clin Infect Dis 43(Suppl 2): S57-S61
13. Martínez JA, Delgado E, Martí S, Marco F, Vila J, Mensa J, Torres A, Codina C, Trilla A, Soriano A, Alquezar A, Castro P, Nicolás JM (2009) Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med 35:439-447
14. Kaye KS, Harris AD, Samore M, Carmeli Y (2005) The case- case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 26:346-351